Navigation Links
DrugRisk Announces Addition of Januvia Cancer Resource Center
Date:4/18/2013

New York, NY (PRWEB) April 18, 2013

The prescription drug safety advocates at DrugRisk.com are announcing the launch of a new resource center for patients who have taken the diabetes drug Januvia, amid warnings that the drug may be related to pancreatic cancer and thyroid cancer.

The goal of DrugRisk is to improve patient safety by providing those taking prescription drugs with the latest warnings, recalls, studies and legal news. Patients can see if others are experiencing similar side effects and decide if they need legal advice.

Januvia is a once-a-day pill introduced in 2006 to help those with type-2 diabetes control blood sugar. It has become Merck’s best-selling drug, with sales over $4 billion last year*.

However, DrugRisk has added a 2011 study from UCLA indicating the drug could increase the risk of pancreatic cancer by 272% and thyroid cancer by 148%**. The Journal for the American Medical Association also recently published findings showing Januvia could double the risk of pancreatitis, which is a risk factor for pancreatic cancer***.

Now, DrugRisk has learned that, with the number of patients filing a Januvia lawsuit alleging cancer growing, lawyers have requested that cases be consolidated to a special federal multi-district court in California****. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452, United States Judicial Panel on Multidistrict Litigation).

Anyone affected by cancer after taking Januvia is encouraged to speak with a lawyer about their legal options. However, due to the specialized nature of federal drug injury cases, DrugRisk only recommends lawyers who have already handled Januvia lawsuits.

For more informati
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related medicine news :

1. DrugRisk Center Announces Court Postponement of NuvaRing Lawsuits
2. DrugRisk Announces Alternative to Mirena IUD May Be Available Soon
3. DrugRisk Announces Updated Information on Mirena Lawsuits
4. DrugRisk Adds Latest Health Warnings and Lawsuit Updates for Yaz
5. DrugRisk Announces New Pradaxa Health Warning From Australia
6. DrugRisk Update: NuvaRing Lawsuit Trials to Begin This Year
7. DrugRisk Update: Court Allows Charges of Prior Fraud Into Pradaxa Lawsuit
8. DrugRisk Pradaxa Lawsuit Update: Court Denys Boehringer’s Protective Order Request
9. DrugRisk Pradaxa Update: Litigation Grows As New Study Adds to Risks
10. DrugRisk Update: Bayer Discloses $500 Million Remaining for Yaz Lawsuits
11. DrugRisk Update: Evidence Submitted in Actos Lawsuit Suggests Drug Maker Knew of Cancer Risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014 Cloud Medical Doctor Software Corporation ... Medical Practice Business Operations solutions and Billing Services for ... Security solutions for all industries announced today that its ... floor of the CME in Chicago by PRICE Futures ... we are very proud of the recognition that our ...
(Date:9/2/2014)... 2014 On August 30, 2014, Harper’s ... “Why You Should Wash Your Face .” According ... global population breathes air considered polluted by the World ... in the skin’s pores destroying its natural oils. These ... radicals that may cause cell damage, redness, aging ...
(Date:9/2/2014)... diagnosed with early-stage breast cancer in California, the percentage ... 2011, although this procedure was not associated with a ... according to a study in the September 3 issue ... surgery for the removal of one breast was associated ... options examined in the study. , Randomized trials have ...
(Date:9/2/2014)... within a few days of discharge do so principally because ... in other parts of the health care system, according to ... Annals of Emergency Medicine ( "Return Visits to the ... asked why they did not follow up as an outpatient, ... wait until their scheduled appointment or being instructed to return ...
(Date:9/2/2014)... Australia (PRWEB) September 03, 2014 Operators ... attend to millions of people annually, arranging care and ... not-for-profit and private enterprises are expected to derive $39.4 ... funding, donations and private income. Over the five years ... an annualised rate of 6.6%, including growth of 4.1% ...
Breaking Medicine News(10 mins):Health News:Cloud Medical Doctor Software Corporation's CEO Interviewed by the Price Futures Group 2Health News:Cloud Medical Doctor Software Corporation's CEO Interviewed by the Price Futures Group 3Health News:Simon Ourian, Kim Kardashian’s Doctor: Air Pollution May Be Aging Your Skin 2Health News:Increase seen in use of double mastectomy 2Health News:Increase seen in use of double mastectomy 3Health News:Discharged patients return to the ER because 'better safe than sorry' 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 3
... for ependymoma, a rare tumor with few treatment ... the effort, which used a new, faster drug ... technology with the first accurate animal model of ... and existing drugs as possible ependymoma treatment candidates. ...
... , THURSDAY, Sept. 15 (HealthDay News) -- Experts ... lead the battle against alcohol abuse. A group ... avoid the harmful effects of excess alcohol, and it also ... has become the third leading risk factor in preventable and ...
... how white blood cells kill diseased tissue using deadly granules, ... The researchers, from Imperial College London and the University of ... see the inner workings of white blood cells at the ... cell rearranges its scaffolding of actin proteins on the inside ...
... Researchers at Cleveland Clinic have received a grant from the ... of a blood test that conclusively identifies concussions in college ... taken before and after a game searches for a ... in elevated levels in an athlete,s blood. Damir Janigro, ...
... For patients with ovarian cancer and their physicians, resistance ... Moffitt Cancer Center have identified a molecular pathway that ... chemotherapy resistance. They are hopeful that the discovery may ... with ovarian cancer; reversing resistance to chemotherapy and improving ...
... Sept. 15 (HealthDay News) -- Not enough children and teens ... for Disease Control and Prevention reveals. Drinking milk is ... although young people need the calcium, vitamin D and other ... consume low-fat milk and milk products to avoid unnecessary fat ...
Cached Medicine News:Health News:New strategy likely to speed drug development for rare cancers 2Health News:New strategy likely to speed drug development for rare cancers 3Health News:Doctors Urged to Lead Battle Against Alcohol Abuse 2Health News:Cancer-killing cells are caught on film in more 3-D detail than ever before 2Health News:Cancer-killing cells are caught on film in more 3-D detail than ever before 3Health News:Cleveland Clinic researchers awarded NIH grant to study concussion-identifying blood test 2Health News:Cleveland Clinic researchers awarded NIH grant to study concussion-identifying blood test 3Health News:Moffitt researchers find possible key to preventing chemotherapy resistance in ovarian cancer 2Health News:Not Enough Kids Drink Low-Fat Milk, U.S. Study Finds 2
(Date:9/2/2014)... Sept. 2, 2014 Reportlinker.com announces that ... its catalogue: BRIC Bariatric Surgery ... http://www.reportlinker.com/p02343483/BRIC-Bariatric-Surgery-Devices-Market-Outlook-to-2020.html BRIC Bariatric Surgery ... Summary GlobalData,s new report, "BRIC Bariatric ... market data on the BRIC Bariatric Surgery Devices ...
(Date:9/2/2014)... 2, 2014 Perrigo Company plc, a public limited ... (the " Company "), today announced that it is ... its new 1.30% Senior Notes due 2016 (the " 2016 ... due 2018 (the " 2018 Exchange Notes "), $800,000,000 of ... Exchange Notes ") and $400,00,000 of its new 5.30% Senior ...
(Date:9/2/2014)... , Spanien und CALGARY, Alberta ... Vorgestellt in der "State of the Art ... 2014    Resverlogix Corp. (TSX: RVX) gab ... Medical Affairs bei Resverlogix, beim Kongress des europäischen Kardiologenverbandes ... einen Vortrag gehalten hat. In seinem Vortrag mit dem ...
Breaking Medicine Technology:BRIC Bariatric Surgery Devices Market Outlook to 2020 2BRIC Bariatric Surgery Devices Market Outlook to 2020 3BRIC Bariatric Surgery Devices Market Outlook to 2020 4BRIC Bariatric Surgery Devices Market Outlook to 2020 5BRIC Bariatric Surgery Devices Market Outlook to 2020 6BRIC Bariatric Surgery Devices Market Outlook to 2020 7BRIC Bariatric Surgery Devices Market Outlook to 2020 8BRIC Bariatric Surgery Devices Market Outlook to 2020 9BRIC Bariatric Surgery Devices Market Outlook to 2020 10Perrigo Company plc Announces Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023 and 5.30% Senior Notes Due 2043 2Perrigo Company plc Announces Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023 and 5.30% Senior Notes Due 2043 3Perrigo Company plc Announces Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023 and 5.30% Senior Notes Due 2043 4RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 2RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 3RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 4RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 5RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 6
... BEIJING , July 12 /PRNewswire-Asia-FirstCall/ -- Concord Medical ... CCM ), the,operator of the largest network of radiotherapy and ... as of July 1, 2010 it has entered,into ... Chang,An,Hospital,s cancer treatment facilities by acquiring a 52% equity interest ...
... , MOUNTAIN VIEW, Calif. , July 12 ... that it has selected AZ-007 ( Staccato zaleplon) for ... move forward into active development.  This decision follows an Alexza ...  In addition, Alexza has created Addicere Therapeutics, Inc., a wholly-owned ...
Cached Medicine Technology:Concord Medical Enters into Joint Venture Agreement with Chang'An Hospital 2Concord Medical Enters into Joint Venture Agreement with Chang'An Hospital 3Concord Medical Enters into Joint Venture Agreement with Chang'An Hospital 4Alexza Pharmaceuticals Updates Staccato® Pipeline and Outlines Pipeline Development Strategy 2Alexza Pharmaceuticals Updates Staccato® Pipeline and Outlines Pipeline Development Strategy 3Alexza Pharmaceuticals Updates Staccato® Pipeline and Outlines Pipeline Development Strategy 4Alexza Pharmaceuticals Updates Staccato® Pipeline and Outlines Pipeline Development Strategy 5Alexza Pharmaceuticals Updates Staccato® Pipeline and Outlines Pipeline Development Strategy 6Alexza Pharmaceuticals Updates Staccato® Pipeline and Outlines Pipeline Development Strategy 7Alexza Pharmaceuticals Updates Staccato® Pipeline and Outlines Pipeline Development Strategy 8
... The ANA and ENA assays ... patients negative for antinuclear antibodies, which ... diseases such as Systemic lupus erythematosus ... disease, progressive systemic sclerosis, scleroderma, polymyositis, ...
... Indirect Fluorescence Assay (IFA) for Anti-native ... for the qualitative and semi-quantitative detection ... nDNA in human serum. Detection of ... be used as an aid in ...
Anti-Tg and Anti-TPO are two major autoantibodies implicated in autoimmune related thyroiditis and aid in the differential diagnosis of Hashimoto's thyroiditis and Graves' disease....
... The Company's first commercial product is the ... single-use, disposable assay devices . The advantages ... are direct use of a vacuum-type blood ... result in minutes. VerifyNow IIb/IIIa, the first ...
Medicine Products: